In navigator, the angiotensin receptor blocker valsartin modestly reduced the progression to type 2 diabetes but had no effect on cardiovascular events in higher-risk patients with impaired glucose tolerance. J Clin Hypertens (Greenwich). 2010 Nov; 12(11):881-5.